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ORIGINAL PAPER
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Abstract
Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prog-
nosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central 
nervous system (CNS) occurs and, in these cases, clinical outcome remains poor. Here, we describe a new and relatively 
rare subgroup of spinal ependymal tumors identified using DNA methylation profiling that is distinct from other molecular 
subgroups of ependymoma. Copy number variation plots derived from DNA methylation arrays showed MYCN amplifica-
tion as a characteristic genetic alteration in all cases of our cohort (n = 13), which was subsequently validated using fluo-
rescence in situ hybridization. The histological diagnosis was anaplastic ependymoma (WHO Grade III) in ten cases and 
classic ependymoma (WHO Grade II) in three cases. Histological re-evaluation in five primary tumors and seven relapses 
showed characteristic histological features of ependymoma, namely pseudorosettes, GFAP- and EMA positivity. Electron 
microscopy revealed cilia, complex intercellular junctions and intermediate filaments in a representative sample. Taking these 
findings into account, we suggest to designate this molecular subgroup spinal ependymoma with MYCN amplification, SP-
EPN-MYCN. SP-EPN-MYCN tumors showed distinct growth patterns with intradural, extramedullary localization mostly 
within the thoracic and cervical spine, diffuse leptomeningeal spread throughout the whole CNS and infiltrative invasion of 
the spinal cord. Dissemination was observed in 100% of cases. Despite high-intensity treatment, SP-EPN-MYCN showed 
significantly worse median progression free survival (PFS) (17 months) and median overall survival (OS) (87 months) 
than all other previously described molecular spinal ependymoma subgroups. OS and PFS were similar to supratentorial 
ependymoma with RELA-fusion (ST-EPN-RELA) and posterior fossa ependymoma A (PF-EPN-A), further highlighting 
the aggressiveness of this distinct new subgroup. We, therefore, propose to establish SP-EPN-MYCN as a new molecular 
subgroup in ependymoma and advocate for testing newly diagnosed spinal ependymal tumors for MYCN amplification.
Keywords Ependymoma · Intradural extramedullary ependymoma · MYCN · Spinal tumor · DNA methylation · CNS 
malignancies
Introduction
Ependymoma comprises a heterogeneous group of primary 
central nervous system (CNS) tumors in children and adults. 
Based on DNA methylation profiling, ependymomas were 
classified into nine distinct molecular subgroups, with three 
in each anatomic compartment of the CNS (supratento-
rial, posterior fossa, and spine) [30, 31]. Spinal ependymal 
tumors account for 21.5% and 18.3% of all primary spinal 
tumors in pediatric and adult patients, respectively, as well 
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as 3–6% of all CNS malignancies in general [9, 18, 29]. 
The three previously established molecular subgroups, spi-
nal subependymoma (SP-SE), spinal myxopapillary epend-
ymoma (SP-MPE), and spinal ependymoma (SP-EPN), 
show relatively good concordance with the histopathologi-
cal subtypes subependymoma, myxopapillary ependymoma, 
and (classic) ependymoma, respectively [31]. SP-SE and SP-
EPN generally arise intramedullary, while SP-MPE occur 
extramedullary and are almost exclusively located at the 
filum terminale or the conus medullaris [1, 7, 20, 37, 38]. 
Spinal ependymal tumors usually grow slowly and are often 
well demarcated. Clinical outcome is generally better than 
that of intracranial ependymomas, with a 5-year OS ranging 
from 60 to 90% [5, 18, 31]. Poor outcome has been described 
in some series, especially for WHO Grade III ependymoma 
[18, 29, 44] which tend to infiltrate the spinal cord and show 
aggressive biological behavior. Treatment of individuals 
with these tumors remains challenging due to the difficulty 
of achieving gross total resections, the paucity of established 
treatment protocols and the uncertainty regarding the thera-
peutic value of radiotherapy [1, 27, 44, 45]. Although spi-
nal ependymal tumors are characterized by distinct somatic 
copy number variations (CNV), e.g. loss of chromosome 6q 
in SP-SE, 22q in SP-EPN, and general chromosomal insta-
bility in SP-MPE, recurrent oncogenic drivers especially in 
aggressive tumors have not yet been identified. [25, 31, 45]. 
Herein, we describe a novel molecular subgroup of spinal 
ependymal tumors using genome-wide DNA methylation 
analysis. These tumors invariably exhibited an aggressive 
clinical course and were molecularly characterized by focal 
high-level amplification of MYCN.
Materials and methods
Tumor material and clinical data
Tumor tissue and retrospectively collected clinical data from 
13 patients with the local diagnosis of spinal ependymal 
tumors (made between 2003 and 2018) were obtained from 
multiple international collaborating centers and collected at 
the Department of Neuropathology of the University Hos-
pital Heidelberg (Heidelberg, Germany). For all cases, a 
genotype check was performed to exclude the possibility 
that material from the same patient was received from more 
than one center. To this end, the Pearson correlation across 
beta methylation values of 59 rs-loci present on both the 
Illumina Infinium HumanMethylation450 and the Illumina 
Infinium HumanMethylation EPIC array were calculated. 
Samples with a correlation ≥ 0.95 were considered as geno-
type match.
Written consent by all patients or their legal representa-
tive was obtained. Research use of tissues, clinical and 
radiological data were in accordance with local ethical 
approvals.
DNA methylation‑based clustering and copy 
number variation plots (CNVs)
Genome-wide DNA methylation profiling was performed 
using the Illumina Infinium HumanMethylation450 and the 
Illumina Infinium HumanMethylation EPIC Kits as previ-
ously described and according to the manufacturer’s instruc-
tions [31].
All computational analyses were performed in R version 
3.4.4 (R Development Core Team, 2019). Raw signal inten-
sities were obtained from IDAT files using the minfi Biocon-
ductor package version 1.24.0 [2, 15]. Illumina EPIC and 
450k samples were merged to a combined data set by select-
ing the intersection of probes present on both arrays (com-
bineArrays function, minfi). Each sample was individually 
normalized by performing a background correction (shift-
ing of the 5th percentile of negative control probe intensi-
ties to 0) and a dye-bias correction (scaling of the mean of 
normalization control probe intensities to 10,000) for both 
color channels. Subsequently, a correction for the type of 
material tissue (FFPE/frozen) and array (450k/EPIC) was 
performed by fitting univariate, linear models to the log2-
transformed intensity values (removeBatchEffect function, 
limma package version 3.34.5). The methylated and unmeth-
ylated signals were corrected individually. Beta-values were 
calculated from the retransformed intensities using an offset 
of 100 (as recommended by Illumina).
Before further analysis, the following filtering criteria 
were applied: removal of probes targeting the X and Y 
chromosomes (n = 11,551), removal of probes containing 
a single-nucleotide polymorphism (dbSNP132 Common) 
within five base pairs of and including the targeted CpG-site 
(n = 7998), probes not mapping uniquely to the human refer-
ence genome (hg19) allowing for one mismatch (n = 3965), 
and 450k array probes not included on the EPIC array. In 
total, 428,230 probes were kept for downstream analysis.
To perform unsupervised non-linear dimension reduction, 
the remaining probes were used to calculate the 1-variance 
weighted Pearson correlation between samples. The result-
ing distance matrix was used as input for t-Distributed Sto-
chastic Neighbor Embedding analysis (t-SNE; Rtsne package 
version 0.13). The following non-default parameters were 
applied: theta = 0, pca = F, max_iter = 2500 perplexity = 20.
To identify fitting samples for this study, DNA-methyla-
tion profiles of 53,468 samples from different tumor entities 
and experimental data were screened and compared with the 
reference cohort of the Heidelberg brain tumor methylation 
classifier which is based on 2682 CNS tumors representing 
82 distinct tumor methylation classes (https ://www.molec 
ularn europ athol ogy.org) [6].
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CNV analysis from 450k and EPIC methylation array 
data was performed using the conumee Bioconductor pack-
age version 1.12.0 (Hovestadt V, Zapatka M, 2017).
Pathology, histology, electron microscopy, 
and immunohistochemistry
Hematoxylin–eosin (H&E)-stained slides were evaluated 
applying the diagnostic criteria provided by the 2016 WHO 
Classification of Tumors of the Central Nervous System 
[24]. Tumors were assessed histologically for the following 
features: cellularity, perivascular pseudorosettes, microvas-
cular proliferation, necrosis, and mitotic activity.
Immunohistochemistry and fluorescence in situ hybridi-
zation were conducted on 1-μm thick formalin-fixed, paraf-
fin-embedded (FFPE) tissue sections mounted on StarFrost 
Advanced Adhesive slides (Engelbrecht, Kassel, Germany) 
followed by drying at 80 °C for 15 min. Immunohistochem-
istry was performed on a BenchMark Ultra immunostainer 
(Ventana Medical Systems, Tucson, AZ, USA).
Antibody Dilution Pretreatment Signal detec-
tion
GFAP Z0334, 
DAKO
1:1000 None Ultraview
EMA GP1.4, Neo-
Markers
1:1000 95 °C, CC1, 
52 min.
Ultraview
Ki67 MIB-1, 
DAKO
1:100 92 °C, CC1, 
64 min.
Optiview
H3K27me3 07–449, 
Millipore, 
Billercia, 
MA
1:1000 95 °C, CC1, 
92 min.
Ultraview
MYCN D4B2Y, Cell 
signaling
1:100 100 °C, CC1, 
64 min.
Optiview
For Ki67 analysis, tumor areas with the highest Ki67 
labelling indices were evaluated for the fraction of positive 
cell nuclei by counting all cells excluding lymphocytes and 
vascular cells in one 200 × microscopic field.
Tissue for ultrastructural examination in one patient was 
retrieved from a paraffin block, rehydrated, post-fixed in 
2.5% glutaraldehyde, and processed and stained for elec-
tron microscopy as per routine protocol. Thin sections were 
examined on a Zeiss 910 electron-microscope.
Fluorescence in situ hybridization (FISH)
Two-color interphase FISH was performed using a target 
probe for MYCN (2p24; green) and AFF3 probe (red) as 
a reference (Zytovision SPEC MYCN/2q11 Dual Color 
Probe). Samples showing sufficient FISH efficiency (> 90% 
nuclei with signals) were evaluated. Signals were scored in 
at least 200 non-overlapping, intact nuclei. Specimens were 
considered amplified for MYCN locus when more than 10% 
of tumor cells exhibited either more than eight signals of the 
corresponding probe with a reference/control ratio > 4.0 or 
innumerable tight clusters of signals of the reference locus 
probe.
RNA sequencing and gene expression profiling
Gene expression profiling was analyzed using two different 
approaches: RNA sequencing and Affymetrix arrays. RNA 
sequencing from fresh frozen tumor material of two patients 
was performed by the High Throughput Sequencing Unit 
of the Genomics & Proteomics Core Facility at the DKFZ 
using the Illumina HiSeq 2000 platform (V4: 125 bp paired 
end reads) and the TruSeq Stranded mRNA Library Prep 
Kit according to the manufacturer’s instructions. The gen-
eral processing of RNA-sequencing data (reads alignment, 
quality control, and counts computation) was performed as 
previously described [26]. Gene expression profiling on the 
Affymetrix GeneChip U133 Plus 2.0 array was undertaken 
for one patient as previously described [43].
Statistics
Age distribution and median age were calculated using R 
(R Core Team, 2017). Survival analysis was performed 
applying the Kaplan–Meier method using GraphPadPrism 
for Windows (Graphpad Software 8.0.2, La Jolla California 
USA, www.graph pad.com). P values comparing the survival 
rates of the respective molecular subgroups were calculated 
using log-rank tests and were rounded to three decimal dig-
its. PFS was defined as the time interval in years between 
first diagnosis and progression of a local tumor or detection 
of distant seeding or local recurrence. OS was defined as 
the time interval between first diagnosis and death. Patients 
were censored at the point of death or loss of follow-up. 
For patient 13, no detailed data regarding OS and PFS were 
available.
Results
DNA methylation profiling reveals an epigenetically 
distinct group of spinal ependymal tumors
Using a screening approach based on unsupervised analysis 
of DNA methylation profiling data of a large set of CNS 
tumors, we identified a distinct cohort of thirteen tumors 
histopathologically diagnosed as ependymoma. When these 
samples were clustered with an extensive set of 53,455 DNA 
methylation profiles covering more than 80 molecularly 
defined classes of CNS tumors, malignancies outside the 
CNS, and experimental data (i.e. cell lines, mouse models 
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and patient-derived xenograft models) in a t-SNE-analysis, 
tumors from this cohort formed a distinct and stable cluster 
(data not shown) [6]. The highest predicted molecular class 
was posterior fossa ependymoma type A (PFA) (12/13) or 
posterior fossa ependymoma type B (PFB) (1/13); how-
ever, due to low calibrated scores samples were previously 
returned as “no matching methylation class” (calibrated 
score < 0.9, MNP Classifier v11b4). Next, we compared the 
methylation patterns of our cohort with a reference set of 
500 ependymomas from all nine major molecular subgroups 
[31] (Fig. 1a). The new group did not cluster with any of the 
other previously described ependymoma subgroups.
MYCN amplification is a characteristic feature 
of the group
DNA methylation array-based CNV plots revealed focal 
high-level MYCN amplification for all 13 samples of the 
cohort (Fig. 1b, c, Suppl. Figure 1a, online resource) and 
several additional chromosomal aberrations at various fre-
quencies, e.g. loss of chromosome 10 (3/13) or focal losses 
on Chromosome 11q (5/13) (Fig. 2d). Patient 1 addition-
ally showed a BRD4 amplification on chromosome 19p 
which was maintained throughout several relapses (Suppl. 
Figure 1b, online resource) and patient 6 showed an addi-
tional YAP1 amplification on chromosome 11. Since MYCN 
amplification is characteristic for aggressive neuroblastomas 
which are often located close to the spine as well as for a dis-
tinct subset of pediatric glioblastomas [13, 21], we repeated 
DNA methylation-based clustering for the distinct spinal 
ependymoma cohort with two reference sets of 105 neu-
roblastomas and 11 MYCN-amplified pediatric glioblasto-
mas, confirming the distinct methylation class of these cases 
(Suppl. Figure 2, online resource). Additionally, CNV plots 
were generated for six relapses (from patients 1 and 2). The 
MYCN amplification remained stable in all six relapsed cases 
(example given in Suppl. Figure 1b, online resource).
MYCN amplification was validated using fluorescence 
in situ hybridization (FISH) in cases for which FFPE tis-
sue could be obtained (n = 5 primary tumors, n = 7 relapsed 
tumors). High-level MYCN amplification was confirmed in 
all available samples (Fig. 2h; Table 1). A limited set of 
RNA sequencing data (n = 2) and gene expression profiles 
generated on the Affymetrix U133 Plus2.0 array (n = 1) 
allowed comparison of MYCN expression levels with a 
cohort of spinal ependymal tumors (n = 18) comprising 
molecular subgroups SP-MPE (n = 8) and SP-EPN (n = 10) 
as well as to a cohort representing all intracranial molecu-
lar subgroups of ependymoma (n = 32) (Fig. 3a, b). MYCN 
amplified samples showed the highest expression of MYCN 
compared to both other cohorts. RNA sequencing did not 
provide significant evidence for additional genetic drivers, 
such as gene fusions (data not shown).
In conclusion, DNA methylation profiling identified a 
novel molecular group of spinal tumors with focal MYCN 
amplification that separates them from previously defined 
molecular subgroups of spinal ependymal tumors and that is 
also distinct from other tumor entities with MYCN amplifica-
tion that may localize in or close to the spinal cord.
Histopathological evaluation demonstrates 
ependymal differentiation and provides evidence 
for malignant progression
All 13 cases of our cohort were independently diagnosed 
as ependymoma by different neuropathologists at 11 cent-
ers in Europe, Australia, and North America. Cases were 
described as ependymoma, WHO Grade II (n = 3, includ-
ing one tanycytic ependymoma) or anaplastic ependymoma, 
WHO Grade III (n = 10). Histopathological evaluation was 
complemented by electron microscopy for one sample of the 
cohort (patient 11) identifying intermediate filaments, ciliary 
structures and zipper-like tight junctions, which are classic 
ultrastructural features of ependymoma (Suppl. Figure 3, 
online resource) [17, 28].
For tumors where material was available (n = 12, five 
primaries and seven relapses), samples were re-evalu-
ated by an experienced neuropathologist from our center 
(D.E.R.) confirming the initial diagnoses (Table 1). All 
tumors exhibited histological signs of ependymal dif-
ferentiation with perivascular pseudorosettes, perivas-
cular GFAP expression, and dot-like positivity for EMA. 
Microvascular proliferation was also frequently observed. 
(Fig. 2a–d, Table 1). Most tumors showed brisk mitotic 
activity and high Ki67 labelling indices (Fig.  2e and 
g). Tumor necrosis was present in most cases and in all 
late manifestations (Fig.  2e–g). H3K27me3, which is 
consistently lost in PF-EPN-A, was retained in all cases 
(Table 1). All tumors showed widespread expression of 
MYCN (Fig. 2h). One primary tumor did not show his-
tological high-grade features, but its recurrence showed 
brisk mitotic activity and overall histological features of 
anaplasia, i.e. evidence of malignant progression (Suppl. 
Figure 4, online resource). Interestingly, while an MYCN 
amplification was detectable in both tumors, the inten-
sity of the immunohistochemical MYCN expression was 
strongly increased in histological high-grade areas of 
the recurrent tumor while low-grade areas present in the 
same FFPE block still showed an only moderate MYCN 
labelling intensity. Different components with high- and 
low-grade morphology in tumors of the other patients also 
provided evidence for a malignant progression during the 
course of disease. The pattern of differential intensity 
of the immunohistochemical MYCN expression in his-
tological low- and high-grade components in the same 
FFPE block was a consistent feature. A strong association 
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Fig. 1  DNA-methylation based 
clustering and CNV analysis 
in SP-EPN-MYCN a t-SNE 
analysis showing DNA-methyl-
ation clustering of the SP-EPN-
MYCN-cohort (n = 13) with 
500 ependymomas of all nine 
major molecular subgroups. 
SP-EPN-MYCN (purple) shows 
distinct methylation patterns 
compared with other molecular 
ependymal subgroups. (Used 
data set for the reference cohort: 
Pajtler et al, Cancer Cell, 2015). 
b CNV-plot of a representa-
tive case (patient 10) showing 
strong MYCN amplification on 
chromosome 2p. Black circles 
mark amplification. c IGV-rep-
resentation of CNV-profiling of 
chromosome 2p for all 13 cases 
showing MYCN amplification 
detected by DNA methylation 
profiling (red arrow). Green 
and red colors mark ampli-
fied and deleted regions of the 
genome, respectively. d Bar plot 
summarizing the most frequent 
CNAs detected in SP-EPN-
MYCN-cases
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between MYCN staining intensity and Ki67 labelling was 
evident (Table 1; Fig. 2). Taken together, this suggests that 
MYCN amplification is an early event in tumorigenesis 
and that malignant progression is associated with a further 
increase in MYCN protein levels.
Given that all tumors of the cohort showed widespread 
immunohistochemical MYCN expression, we evaluated 
whether immunohistochemical MYCN expression may serve 
as a surrogate marker for MYCN amplification. We stained 
20 spinal ependymomas without MYCN amplification, 10 
of the methylation group SP-EPN and 10 of the methyla-
tion group SP-MPE. None of these tumors showed a strong 
expression of MYCN. While the majority of cases showed 
no immunolabelling at all or only occasional positive cells, 
MYCN-amplified tumors showed a clearly distinct staining 
pattern with widespread and usually strong immunohisto-
chemical MYCN expression (Fig. 4).
Considering these findings as well as the results of the 
molecular analysis, which showed MYCN amplification as 
the characteristic copy number alteration in these tumors, 
we suggest to designate this new subgroup “Spinal Epend-
ymoma with MYCN amplification” (SP-EPN-MYCN).
Demographic and radiological features 
of SP‑EPN‑MYCN
Demographic and basic radiological data were available for 
13/13 and 11/13 of SP-EPN-MYCN tumors, respectively. 
Fig. 2  Histological features of 
SP-EPN-MYCN Highly cellular 
neuroectodermal tumor with a 
perivascular pseudorosettes, b 
microvascular proliferation, c 
perivascular enhanced GFAP 
expression, d dot-like EMA 
positivity, e brisk mitotic activ-
ity, f tumor necrosis, g high 
Ki-67 labelling, and h extensive 
nuclear MYCN expression. 
Inset in h): Results of two- color 
fluorescence in situ hybridiza-
tion demonstrating multiple 
green signals for the MYCN-
locus-probe and 2 red signals 
for the centromeric control 
probe. Scale bar = 300 µm in a, 
100 µm in b, d, g, h, 200 µm in 
c, f and 50 µm in e 
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Information regarding metastatic spread at diagnosis and 
during the course of disease could be obtained for 10/13 
patients, respectively (Figs.  5 and 6, Suppl. Figure  5, 
online resource). Median age of onset was 32 years (range 
12–56 years) and, therefore, lower than in previous stud-
ies on spinal ependymal tumors which reported a median 
age of about 40 years [7, 18] (Fig. 5a). Patient gender was 
evenly distributed across the cohort with seven female and 
six male cases (Fig. 5b). Next we asked whether there is 
a predilection site for SP-EPN-MYCN similar to SP-MPE 
and SP-EPN, which are mostly located at the conus med-
ullaris/filum terminale and in the cervical/thoracic spine, 
respectively [7, 31]. Exact location in relation to the spinal 
meninges could be determined from radiological data of 
seven SP-EPN-MYCN patients. For all of these, the primary 
tumor was located intradurally and extramedullary (Fig. 5c). 
The majority of the cases arose in the cervical or thoracic 
spinal cord (n = 10), with only one case showing lumbar 
localization at initial presentation. Primary lesions were 
large, with only one case being limited to a single spinal 
segment. Nine out of ten cases showed multi-locular, diffuse 
leptomeningeal dissemination at diagnosis, including intrac-
ranial metastases in three cases. Diffuse leptomeningeal 
spread at some point throughout the course of disease was 
reported in all patients (10/10), including the two cases that 
did not show metastatic spread at first presentation. How-
ever, dissemination was not limited to the leptomeninges, 
but included nodular lesions as well. Cystic compartments 
within the malignant lesions were reported in four of the 
seven patients for whom radiological footage was available. 
Representative radiological images of an SP-EPN-MYCN 
tumor in a 46-year-old female patient are given in Fig. 6 
(see also: Suppl. Figure 5, online resource). In conclusion, 
SP-EPN-MYCN tumors were mainly diagnosed in adoles-
cence and early adulthood and showed distinct radiological 
features, including extramedullary location and diffuse lep-
tomeningeal spread, thus differing strongly from previously 
described spinal ependymoma cases [37, 45].
SP‑EPN‑MYCN show dismal outcome despite high 
intensity treatment
Detailed clinical data were collected and subsequently 
analyzed in 12 of 13 cases. The SP-EPN-MYCN cohort 
showed aggressive behavior, including early metastases, 
rapid progression after relapse, dissemination throughout 
the whole CNS, and resistance to common treatment strate-
gies. Successful gross total resection of the primary tumor 
was reported for one patient only (1/12) but could not be 
achieved in others (11/12) due to metastatic spread at diag-
nosis (9/12) or extended lesions that would have resulted 
in non-acceptable side effects from surgery (2/12). In the 
majority of cases, surgery was the initial therapeutic step Ta
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Fig. 3  MYCN expression in 
SP-EPN-MYCN compared to 
other molecular ependymoma 
subgroup. a Relative level of 
MYCN expression in a sample 
from patient 2 was compared to 
MYCN expression in SP-MPE 
(n = 8) and SP-EPN (n = 10) 
(Affymetrix U133 Plus2.0 array 
data). b MYCN expression in 
samples from patient 2 and 3 
determined by RNA-sequencing 
compared to 34 samples repre-
senting all intracranial molecu-
lar subgroups of ependymoma 
(n = 34)
Fig. 4  Immunohistochemical 
MYCN expression in spinal 
ependymomas. a Strong and 
widespread expression of 
MYCN in a SP-EPN-MYCN 
tumor that was diagnosed as 
grade III. b Moderate but wide-
spread expression of MYCN in 
a SP-EPN-MYCN tumor that 
was diagnosed as grade II. c 
SP-EPN with sparse expression 
of MYCN in a few tumor cells. 
d Example of SP-EPN without 
expression of MYCN. Scale 
bar = 100 µm
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(9/12) (Fig. 7). All patients relapsed or progressed, often 
with metastatic spread, at some point during the course of 
disease. Figure 7 and Suppl. Table 1 summarize applied 
treatment strategies for all cases. Despite highly intensive 
treatment regimens, including repeated surgery, radiother-
apy, different chemotherapy protocols, and targeted therapy, 
six patients were deceased and one was at a terminal disease 
stage at time of data collection. Of the remaining six cases, 
two were diagnosed in late 2018; thus, data on follow-up are 
limited. Chemotherapy was applied as single agent or com-
binatorial treatment including temozolomide, carboplatin, 
etoposide/cyclophosphamide, etoposide/carboplatin, vin-
cristine/cyclophosphamide, and trofosfamide. In one patient, 
Imatinib was used due to high c-Kit expression of the tumor 
cells. Figure 8 shows survival of SP-EPN-MYCN (n = 12) 
compared to a reference set of cases of the three other 
molecularly defined spinal ependymal subgroups (Fig. 8a, 
b) as well as ST-EPN-RELA and PF-EPN-A (Fig. 8c, d). 
As reference sets for the subgroups SP-SE (n = 5), SP-EPN 
(n = 9), ST-EPN-RELA (n = 76), and PF-EPN-A (n = 219), 
data published by Pajtler et al. in 2015 [31] were used. 
For myxopapillary ependymoma (n = 19), a histologically 
defined reference set from Kraetzig et al. 2018 [22], was 
used due to a lack of sufficient numbers for molecularly 
defined SP-MPE with clinical data. Notably, a limited set of 
clinical data on molecularly defined SP-MPE that was not 
included showed identical clinical outcomes to histologi-
cally classified myxopapillary ependymoma from Kraetzig 
et al. 2018 [31]. The median PFS for SP-EPN-MYCN was 
17 months and was significantly worse than for SP-SE 
(p = 0.006), SP-EPN (p = 0.001) and SP-MPE (p = 0.008) 
(Fig. 8a). No disease-related death was reported for any of 
the other spinal subgroups, whereas SP-EPN-MYCN showed 
a median OS of 87 months and dismal outcome compared 
Fig. 5  Clinicopathological variables of SP-EPN-MYCN. a Histogram 
depicting age of onset at first diagnosis. Red line marks the median 
(32 years). b Gender distribution was even with six male and seven 
female patients. c Schematic transversal depiction of the spinal cord 
showing extramedullar, intradural localization of tumors as reported 
in seven patients. d Localization of primary tumors and metastases 
throughout the CNS. Information regarding the localization of pri-
mary tumors and metastatic spread was available in 11/13 and 10/13 
patients, respectively. Several patients showed multiple sites of met-
astatic spread. Localization of the primary lesion is shown in red, 
localization of metastases at diagnosis is shown in yellow, metastatic 
spread throughout the course of disease is shown in green. For two 
patients information regarding the localization at diagnosis was only 
given as “spinal” (blue circles)
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with SP-SE (p = 0.166), SP-EPN (p = 0.050), and SP-MPE 
(p = 0.005) (Fig. 8b).
Since spinal ependymal tumors are known to have a rela-
tively benign prognosis in general, we also compared SP-
EPN-MYCN tumors with ST-EPN-RELA, and PF-EPN-A, 
as these two subgroups show the worst prognosis of all so 
far described molecular ependymoma subgroups [31]. There 
was no significant difference in OS between SP-EPN-MYCN 
and ST-EPN-RELA (p = 0.252) or PF-EPN-A (p = 0.353) 
(Fig. 8c). Notably, PFS was significantly worse in SP-EPN-
MYCN compared with PF-EPN-A (p = 0.017), and ST-EPN-
RELA (p = 0.047) (Fig. 8d).
In conclusion, SP-EPN-MYCN showed significantly 
reduced PFS and OS compared to all other spinal epend-
ymoma entities and similar prognosis as unfavorable intrac-
ranial subgroups ST-EPN-RELA and PF-EPN-A, thus con-
firming the highly aggressive nature of this newly defined 
molecular subgroup of spinal ependymal tumors.
Discussion
In this study, we identified and characterized a novel 
molecular subgroup of spinal ependymoma designated as 
SP-EPN-MYCN with histological features of ependymoma 
and a characteristic MYCN amplification. MYCN belongs 
to the family of MYC-oncogenes and is an important regu-
latory gene during neuronal embryogenesis [19]. It plays 
a major role in the formation and proliferation of a wide 
range of malignancies, including neuroblastoma, pediatric 
glioblastoma, medulloblastoma, nephroblastoma, leukemia, 
prostate cancer, and lung cancer, and often correlates with 
poor prognosis [3, 4, 10, 21, 23, 32, 34, 42]. Scheil et al. 
reported on two cases of spinal MYCN-amplified epend-
ymoma staged as WHO Grade II and WHO Grade III, 
respectively [35]. Both tumors showed histopathological 
patterns that were similar to cases described in our study. 
For one of these cases, relapse, metastatic spread into the 
subarachnoid space and intracranially was documented. 
Notably, the WHO Grade II tumor in their study showed the 
same pattern of malignant progression at relapse as those 
in our study [35]. Interestingly, their second case was also 
characterized by multiple schwannomas, indicating a possi-
ble NF2-syndrome in the affected patient. Patients described 
in our study did not show any signs related to NF2 and no 
NF2 mutations were found in both patients for whom RNA-
sequencing was available. One patient was diagnosed with 
an embryonal testicular tumor 2 years before the detection 
of the spinal ependymoma. There is no clear evidence for a 
correlation of SP-EPN-MYCN with a cancer predisposition 
syndrome, although the cohort is too small to finally answer 
this question. Since we could not detect any other major 
genetic aberration apart from a YAP1 amplification and a 
Fig. 6  Radiological scans and intraoperative photograph of patient 
12 a sagittal cervical MRI-T2 scan, red asterisk marks intradural, 
extramedullar tumor (C7) b sagittal cervical contrast enhanced MRI-
T1 scan c sagittal MRI-T2 scan, the spinal canal is filled with widely 
disseminated tumor masses d and e F-18-FDG PET-CT (transversal, 
C7 (d) and sagittal, whole spine (e)) shows raised metabolism corre-
sponding with the tumor at level C7 f intraoperative photograph taken 
during initial biopsy showing intradural mass
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Fig. 7  Visualization of therapy regimens used in individual patients 
of the SP-EPN-MYCN cohort Each box represents one therapeutic 
intervention, boxes connected with a black line were given as com-
bination treatment. The sequence of the boxes represents the chrono-
logical order of therapeutic steps, apart from patient 9 for whom only 
limited data was available and therefore the exact chronological order 
of therapy events could not be reconstructed. The date indicates the 
year of the initial diagnosis. Biopsies were not counted as therapeutic 
interventions and are not listed, but took place in every patient (See 
also: Supp. Table 1)
Fig. 8  PFS and OS of SP-EPN-MYCN (n = 12) analyzed using 
Kaplan–Meier curves. a PFS and b OS of SP-EPN-MYCN were com-
pared with all other molecular spinal ependymal subgroups as well 
as c, d ST-EPN-RELA and PF-EPN-A. P values were calculated 
using log-rank-tests between the molecular subgroups. ns = p  > 0.05, 
* = p < 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. No survival data was 
available for patient 13. (Pajtler et al. 2015; Kraetzig et al. 2018)
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BRD4 amplification each in one case, we strongly assume 
that MYCN amplification is the main driving oncogenic 
event in SP-EPN-MYCNs as is also known for aggressive 
neuroblastoma, in which MYCN amplification is sufficient 
for tumor formation and progression [41]. This hypothesis 
is further supported by the fact that MYCN amplification 
was retained in all relapses and by a recurrent immunohis-
tochemical MYCN expression pattern suggesting malig-
nant progression being associated with a further increase in 
MYCN abundance. Notably, it was previously shown that 
transcription of MYCN in MYCN amplified neuroblastoma 
cells relies on BRD4 expression and that BRD4 inhibition 
by BET-bromodomain inhibitors decreases MYCN expres-
sion [14, 33].
In contrast to SP-EPN that are mostly located in the center 
of the spinal cord [37, 38], all cases for which we were able 
to obtain detailed information were located intradural and 
extramedullary. The distinct methylation patterns of the dif-
ferent spinal ependymoma subgroups may be indicative of 
dissimilar cells of origin. Intradural, extramedullary epend-
ymoma apart from SP-MPE is very rare and only sparse 
information regarding these tumors is available in the lit-
erature. Several case reports describe patients that showed 
similar features as SP-EPN-MYCN, such as multilocular 
disease, diffuse leptomeningeal spreading and characteris-
tic ependymal histological features [11, 16, 36]. Notably, a 
previous study reports on a pediatric case in which nodu-
lar lesions were detectable in an MRI scan 2 years prior 
to onset of disease-related symptoms [36]. Their review of 
the literature revealed 24 cases of intradural, extramedullary 
ependymomas with varying outcome but common epide-
miological and radiological features, i.e. localization within 
the cervical/thoracic spine, occurrence in adulthood and a 
higher prevalence in females. While several of the reported 
cases might represent SP-EPN-MYCN tumors with poor 
prognosis, others showed different characteristics, suggest-
ing that rare cases of intradural extramedullary ependymoma 
with favorable outcome may exist apart from the molecular 
subgroups SP-MPE and SP-EPN-MYCN.
While the majority of spinal ependymomas are relatively 
benign and show favorable outcome, several epidemiological 
studies in the past reported a subset of patients with highly 
aggressive disease and poor survival [7, 18]. These cases 
were often diagnosed as anaplastic ependymoma WHO 
Grade III and it is likely that these represented tumors of 
the SP-EPN-MYCN subgroup. However, in our study three 
cases were initially diagnosed as ependymoma WHO Grade 
II, and all these tumors showed malignant progression his-
tologically and clinically. We, therefore, propose that all 
cases of spinal ependymoma should be analyzed for the 
presence of an MYCN amplification, especially if they show 
disseminated disease at diagnosis. Based on our data, DNA 
methylation analysis is a suitable diagnostic tool which also 
supports unambiguous molecular classification [6]. IHC 
stainings for MYCN might serve as a suitable pre-screening 
method. In case SP-EPN-MYCN is diagnosed, a cranial MRI 
should be performed to exclude intracranial metastases as 
these were seen in three patients of our cohort at initial diag-
nosis. Close radiological monitoring also seems appropriate 
due to the fact that newly emerging metastases tended to 
show rapid growth.
We suggest to establish SP-EPN-MYCN as an additional 
major molecular subgroup of ependymoma. Given its clear 
diagnostic criteria and clinical impact SP-EPN-MYCN 
should also be in included in the next update of the WHO 
classification of tumors of the CNS. Regarding the devas-
tating outcome of SP-EPN-MYCN, there is an urgent need 
for innovative therapeutic concepts for these patients. Due 
to the small patient cohort and the wide range of therapeu-
tic strategies, it is not possible to draw conclusions regard-
ing optimal treatment for SP-EPN-MYCN from our study. 
Although MYCN is currently still seen as an undruggable 
target, several strategies of MYCN-inhibition are currently 
being investigated. Amongst them, HDAC inhibitors, PARP 
inhibitors, Aurora A-kinase inhibitors and BET-bromodo-
main inhibitors are seen as promising candidates for trans-
lation into the therapy for MYCN-amplified tumors [4, 8, 
12, 14, 33, 40]. There is also evidence that MYCN might 
be targetable through immunotherapy [39]. Whether one 
of these strategies is suitable for treating SP-EPN-MYCN 
tumors remains to be seen and should be investigated in 
future clinical trials.
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